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Facioscapulohumeral Muscular Dystrophy (FSHD) is an autosomal dominant neuromuscular 
disease affecting 1 in 20,000 to 1 in 15,000 individuals and is characterized by progressive 
weakness in the facial, scapular, humeral, truncal, and lower extremity muscles (Tawil and 
Van Der Maarel Muscle Nerve 2006). FSHD is associated with the contraction of the D4Z4 
microsatellite repeat below a threshold number of repeats (Wijmenga et al., Nat. Genet, 
1992), allowing the transcription of the DUX4 gene contained within the last repeat 
(Snider et al., PLoS Gen, 2010). The disease only develops when DUX4 is expressed 
from a chromosome with the permissive 4qA allele, which contains a polyadenylation 
signal (PAS) that stabilizes the DUX4 transcript (Lemmers et al., Science, 2010). We are 
using CRISPR technology to investigate the possibility that disruption of the PAS in cells 
derived from FSHD patients could prevent expression of the DUX4 protein and restore 
the cell to a less affected phenotype. We will then take advantage of the high 
reprogramming efficiency of FSHD cells and generate iPSC from FSHD muscle cells 
with the repressed DUX4 allele, and determine if they have a similar phenotype to iPS 
cells derived from non-affected individuals. Finally, we will use the highly-engraftable iPS 
cells in xenograft experiments to determine if the DUX4-silenced iPSCs repopulate 
injured muscle more efficiently than unaltered FSHD-derived iPSC, and evaluate their 
potential for use as therapeutics. 
 
